Pfizerâs $70 billion deal with the U.S. government is essentially a PAY-OFF, granting preferential treatment and helping Pfizer avoid accountability
Pfizer’s $70 billion deal with the U.S. government is essentially a PAY-OFF, granting preferential treatment and helping Pfizer avoid accountability As Pfizer basks in record-breaking profits from its COVID-19 vaccine—now the most lucrative pharmaceutical product in history—the company has quietly …
Read More